spacer
home > ebr > winter 2002 > absolute or limited product protection for biotech inventions under the relevant ec directive
PUBLICATIONS
European Biopharmaceutical Review

Absolute or Limited Product Protection for Biotech Inventions under the relevant EC Directive

Current discussion about the scope of protection of product patents in the field of biotechnology was sparked by EC Directive 98/44 on the protection of biotechnological inventions (hereafter referred to as BIO-DIR). It was to be implemented on 30th July 2000 and has since given rise to considerable controversy in the contractual states. The nullity suit in the Netherlands, which received support from Italy and Norway, was rejected by the European Court of Justice (ECJ) on 9th October 2001. To date only Great Britain, Ireland, Denmark, Finland and Greece have followed their duty of implementation. Now there is increasing pressure on the so far hesitant states to ratify a national law of implementation. Due to the ongoing debate on the ethical aspects of gene patenting, the German Parliament has not yet decided on the draft of this law, nor on the product protection for gene sequences.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Uta Kцster, Associate with Bardehle Pagenberg Dr Uta Kцster is an Associate with the Munich-based intellectual property law firm Bardehle Pagenberg Dost Altenburg Geissler. The firm provides the combined services of patent attorneys and attorneys-at-law, offering prosecution, litigation and counselling in all matters related to intellectual property, covering all fields of technology.
Dr Kцster is an Attorney-at-Law with a doctorate degree in Biology. She is active in counselling and litigation, with a practice focus on patent law, in particular biotechnology patents.

spacer
Dr Uta Kцster
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Conveying Medical Guidance in Clinical Trials – A Survey

Europital Medical Consultancy

With the incremental demand for proactive safety surveillance throughout the conduct of clinical trials, the role of Medical Management is at the fore in ensuring the safety and wellbeing of the participants. The complex responsibilities of a Medical Monitor (MM) starts from the design and development phase, through to study close out. Understanding the principle behind the protocol and the prospective medical solution the study would deliver forms the bloodline for the MM role. Often, the MM is the face of contact for both the site personnel and the study team members with regard to medical, safety and scientific issues within the project. When it comes to medical guidance, the communication channel used to deliver solutions contributes to a large extent in effectively managing decisive situations. Our previous study on acquiring medical guidance from an operations team perspective revealed that e-mails were the most used communication method (see the article, 'Talking Points', in ICT November 2014). In our efforts to further strengthen the mode of medical guidance delivery, we designed a survey to study the existing trend and constraints in this communication chain management, as outlined here.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement